NKT cells are characterized by their production of both T h 1 and T h 2 cytokines immediately after stimulation with a-galactosylceramide (a-GalCer), which is composed of a-galactopyranose linked to ceramide (itself composed of sphingosine and fatty-acyl chains); the chain length of the ceramide varies and this affects the ability of a-GalCer to stimulate cytokine production. However, the contribution of its galactopyranose sugar moiety remains unclear. We synthesized a-carba-GalCer, which has an a-linked carba-galactosyl moiety; here, the 5a#-oxygen atom of the D-galactopyranose ring of a-GalCer is replaced by a methylene group. The a-carba-GalCer was more stable and showed higher affinity to the NKT receptor. It thus enhanced and prolonged production of IL-12 and IFN-g compared with a-GalCer, resulting in augmented NKT cell-mediated adjuvant effects in vivo. The a-carba-GalCer, which has an ether linkage, was more resistant to degradation by liver microsomes than was a-GalCer, which has an acetal bond. Modulation of the sugar moiety in glycolipids might therefore provide optimal therapeutic reagents for protective immune responses against tumor or pathogens.
Induction of T h 1-biased cytokine production by a-carba-GalCer, a neoglycolipid ligand for NKT cells Takuya Tashiro Introduction NKT cells express an invariant TCRa chain encoded by a Va14-Ja18 or a Va24-Ja18 gene in mice (1) or humans (2, 3) , respectively. NKT cells recognize CD1d-restricted glycolipids, such as a-galactosylceramide (a-GalCer), and rapidly produce T h 1 cytokines, for example IFN-c, and T h 2 cytokines, for example IL-4 (1). NKT cell production of IFN-c mediates strong adjuvant effects for protective anti-tumor immune responses because of IFN-c-mediated activation of NK cells and CD8 + killer T cells (4) (5) (6) . On the other hand, T h 2 cytokine production, such as IL-10, enhances regulatory immune responses and prevents development of certain autoimmune diseases (7, 8) . Thus, it has long been thought desirable to regulate the function of NKT cells by using optimized glycolipid ligands, for example by modulating their ceramide or sugar moieties, which would possibly increase the stability of the TCR-CD1d-glycolipid triple complex.
The antigen-binding sites of mouse and human CD1d molecules are composed of two large hydrophobic pockets, designated A# and F#, that can accommodate the fatty-acyl chain and the sphingosine chain of ceramide, respectively (9, 10) . Up to 26 carbon atoms of the acyl chain can be anchored on the A# pocket, whereas 18 carbon atoms are anchored on the F# pocket. We have previously shown that glycolipids with these lengths of alkyl chains are the most effective in stimulating NKT cells (11) , suggesting that the optimized alkyl chain lengths lead the most stable association with CD1d molecule and the production of both T h 1 and T h 2 cytokines. McCarthy et al. (12) have also shown that the lengths and saturation of both alkyl chains affect the stability of binding to CD1d, resulting in a modulated NKT cell TCRbinding affinity and immunological synapse formation. Furthermore, it has been reported that OCH (an a-GalCer analogue with a truncated sphingosine chain) induces T h 2-biased cytokine production because of the low affinity of OCH to CD1d (13) . OCH has been shown to diminish NKT cell IFN-c production and CD40 ligand (CD40L) expression because of the failure of antigen-presenting cells (APC) to produce IL-12 (14) . On the basis of these findings, the stability of the CD1d-glycolipid complex has been considered to be the major factor that could evoke the shifted cytokine production by affecting the association of glycolipids with the CD1d molecule.
The above-mentioned hydrophobic interactions of the alkyl chains on a-GalCer affect its structure and function as a glycolipid ligand. Recent studies on crystal structures have revealed that the 3-hydroxyl group on the sphingosine chain and the 2-hydroxyl group on the D-galactopyranose moiety of a-GalCer bind to form hydrogen bonds with Arg95 and Gly96, respectively, in the complementarity-determining region (CDR) 3 of the human invariant NKT TCR Va24Ja18 (9) . These findings suggest that the sugar moiety is also important to make a stable NKT TCR-a-GalCer-CD1d complex. Therefore, in the generation of neoglycolipids with desired NKT cell function, it is necessary to consider structural modification of the sugar moiety of the NKT cell ligands.
Here, we demonstrated that a new synthetic a-GalCer analogue, a-carba-GalCer, in which the 5a#-oxygen atom of the pyranose ring of D-galactose is replaced by a methylene group, evoked a potent T h 1-biased response and augmented NKT cell-mediated adjuvant effects in vivo. Since a-carba-GalCer has a stable ether linkage, it is likely to be resistant to galactosidase and thus be structurally stable in vivo. Moreover, the replacement of the O atom of D-galactose by a CH 2 group generated a new hydrophobic interaction with Pro28 on CDR1 of the invariant NKT TCRa chain, resulting in their stable interaction.
Methods

Mice
Specific pathogen-free C57BL/6 (B6) mice were purchased from Charles River (Kanagawa, Japan) and TAP À/À B6 mice were kept under specific pathogen-free conditions and used at 8-16 weeks of age. All experiments were in accordance with protocols approved by RIKEN Animal Care and Use Committee.
Reagents
The a-carba-GalCer was synthesized as described previously (15) . One milligram of a-carba-GalCer was dissolved in dimethyl sulfoxide and diluted with saline to adjust the concentration to 200 lg ml À1 . The a-GalCer was purchased from Funakoshi (Tokyo, Japan). LPS-free ovalbumin (OVA) was from Seikagaku Corp. (Tokyo, Japan). Analysis of cell surface markers or intracellular cytokine staining and cell sorting was performed using the following mAb or recombinant proteins in FACS analysis: fluorescent isothiocyanate (FITC) anti-TCRb (H57-297), mouse CD1d-mouse IgG1 fusion protein (Dimer X), APC-conjugated anti-mouse IgG1 (X56), allophycocyanin anti-mouse CD11c (HL3), phycoerythrin (PE) anti-mouse IL-12 (C15.6), FITC anti-mouse CD8a (53-6.7), peridinin-chlorophyll protien-Cy5.5 B220 (RA3-6B2), APC anti-mouse IFN-c (XMG1.2) (BD Biosciences, San Diego, CA, USA), PE anti-human Va24 TCR (C15), FITC anti-human Vb11 TCR (C21) and Pacific Blue anti-human CD4 (RPA-T4) (eBioscience, San Diego, CA, USA). The a-carba-GalCer or a-GalCer-loaded CD1d dimers were prepared as described previously (16) . For in vivo neutralizing experiments, goat polyclonal IgG specific for anti-mouse IL-12 and anti-mouse CD40L was used and purchased from R&D systems (Minneapolis, MN, USA).
Cytokine measurement
The cytokine concentrations in plasma or culture supernatants were quantified by a cytometric bead array (BD Bioscience) and mouse IFN-c ELISA kit (Thermo Scientific Endogen, Rockford, IL, USA) according to the manufacturer's protocol.
Flow cytometry and cell sorting
Spleen or liver mononuclear cells (MNCs) from mice and PBMCs from human healthy volunteers were isolated as described previously (16) . Flow cytometry was performed using a FACSCalibur and CELLQuest (BD Biosciences) or FACSAria and FACSDiVa (BD Biosciences). FlowJo software (Tree Star, Ashland, OR, USA) was used for analysis; all the data were live gated based on forward and side scatter and propidium iodide exclusion. For isolation, cells were sorted by an FACSDiVa and FACSAria (BD Biosciences), and the purity of sorted cells was usually >99%.
Intracellular cytokine staining
Intracellular cytokine staining was performed as described previously (16) . The adjuvant activities of NKT cells were assayed as described previously (5) . Briefly, spleen cells from TAP À/À mice were incubated with hypertonic medium in the presence of 10 mg ml À1 OVA and then incubated with hypotonic medium to induce apoptosis. This cell-associated form of OVA was injected intravenously (2 3 10 7 cells per mouse) together with a-GalCer or a-carba-GalCer (2 lg per mouse) into B6 wild-type mice on a B6 background. After 7 days, spleen cells were stimulated in vitro with 1 lM OVA 257-264 peptide for 6 h and then IFN-c production by CD8 + T cells was monitored by intracellular staining.
NK cell-mediated cytotoxicity NK cell-sensitive YAC-1 lymphoma cells were used as target cells. Target cells (2 3 10 6 ) were labeled for 60 min at 37°C with 100 lCi of Na 51 CrO 4 in 200 ll of serum. Then, they were washed three times with medium and subjected to a cytotoxicity assay. Labeled target cells (2 3 10 3 cells per well) were incubated with spleen cells or liver MNCs (prepared from B6 mice) previously treated with ligands for 4 h at 37°C in 96-well round-bottom plates. The plates were then centrifuged, the resulting supernatants were harvested and their content of radioactivity was determined with a gammacounter (PerkinElmer, Waltham, MA, USA).
In vitro stimulation of mouse NKT cells
Bone marrow-derived DCs (BMDCs) were raised from bone marrow precursors in the presence of granulocyte macrophage colony-stimulating factor (GM-CSF) (5 lg ml À1 ) for 6 days (17) and were incubated with either glycolipid a-GalCer or a-carba-GalCer for 2 h in a 37°C CO 2 incubator before co-culture with NKT cells. After washing the glycolipidloaded BMDCs in ice-cold RPMI1640 medium (with 2% FCS) three times, 0.2 million NKT cells were isolated by FACSAria (Beckton Dickinson), at a purity of >99%, and were seeded onto the glycolipid-pulsed BMDCs in a total volume of 200 ll and co-cultured for the indicated times. In the case of blocking experiments, NKT cells were incubated with anti-CD40L mAb (clone MR1, BD Biosciences) before the addition of BMDCs for 30 min in a 37°C CO 2 incubator. Similarly, BMDCs were incubated with anti-IL-12 receptor b2 mAb (clone HAM10B9, BD Biosciences) before the addition of NKT cells. All in vitro stimulations of NKT cells were performed in a 37°C CO 2 incubator for the indicated times.
Surface plasmon resonance
The affinity and kinetic properties of 'invariant' Va14/Vb8.2 binding to a-carba-GalCer-CD1d or a-GalCer-CD1d complexes were measured with a spectrometer (model3000, Biacore, Buckinghamshire, UK) as previously described (18) . The recombinant CD1d loaded with a-carba-GalCer or a-GalCer was immobilized onto CM5 sensor chips (Biacore) at a level of 1000 resonance units. In all experiments, glycolipidunloaded CD1d was used as a negative control. Equilibrium binding was performed at a flow rate of 10 ll min À1 from the lowest concentration of Va14/Vb8.2. Equilibrium dissociation constants (K d ) values were calculated using the standard hyperbolic model. The kinetics of the Va14/Vb8.2-CD1d-glycolipid interactions were measured at 50 ll min 
Analysis of glycolipid stability
The a-GalCer (100 ng) or a-carba-GalCer (100 ng) was incubated with mouse liver microsomes (50 lg) (BD) for 24 or 48 h at 37°C. Glycolipids were recovered by extraction with chloroform and used for stimulation of whole spleen cells to analyze IFN-c production.
In vitro stimulation of human PBMCs
Human PBMCs from healthy volunteers were prepared as previously described (16) . CD14
+ monocytes were positively selected by MACS (Miltenyi Biotech, Bergisch Gladbach, Germany) and CD14 À PBMCs were stored at À80°C for 5 days. Monocyte-derived DCs (MoDCs) were generated from CD14 + monocytes by culturing with GM-CSF (50 ng ml À1 ) and IL-4 (100 ng ml À1 ) for 5 days. After generation of DCs, CD14 À1 PBMCs (10 5 cells per 100 ll) were co-cultured with MoDCs (10 4 cells per 100 ll) in the presence or absence of glycolipid and NKT cell expansion and cytokine production were analyzed.
Statistics
Data are presented as mean values 6 SD. Student's t-test was used to determine statistical significance between groups, with P <0.05 being considered significant.
Results
Synthesis of a neoglycolipid, a-carba-GalCer, by the replacement of the 5a#-oxygen atom of the pyranose ring of D-galactose on a-GalCer by a methylene group According to the crystal structure of a-GalCer-CD1d (9, 19), the glycosidic oxygen atom of a-GalCer makes a hydrogen bond with CD1d (mouse: Thr156 and human: Thr154) and plays an important role in making a stable complex. In addition, it is known that the ether-linked analogue of a-GalCer, a-C-GalCer, induces T h 1-biased cytokine production (20) . On the basis of these results, we synthesized a carbocyclic analogue, a-carba-GalCer (Fig. 1) , with a linking oxygen atom and hence an ether linkage. A detailed procedure for synthesis of a-carba-GalCer has already been reported (15) . The synthetic a-carba-GalCer possesses all the hydroxyl groups of a-GalCer, so that it satisfies the structural requirements for making the complex with the NKT TCR and CD1d.
a-carba-GalCer exhibits enhanced T h 1-biased cytokine production in vivo
The staining profiles of NKT cells with a-carba-GalCer were first investigated by using a-carba-GalCer-loaded soluble recombinant CD1d according to the protocols published (21) (22) (23) . The a-carba-GalCer-loaded CD1d dimer stained mouse NKT cells, similarly to those stained with an a-GalCer-loaded CD1d dimer ( Fig. 2A) . To examine the functional activity of a-carba-GalCer, we administered a-carba-GalCer or a-GalCer intravenously and monitored serum cytokine levels ( Fig. 2B and C) . The administration of a-carba-GalCer (2 lg) resulted in enhanced and longlasting production of IFN-c, which peaked at 36 h after stimulation, whereas IFN-c production by a-GalCer peaked at 12 h (Fig. 2B) . IL-12p70, which is important for production of IFN-c, also showed prolonged and enhanced production after a-carba-GalCer administration compared with a-GalCer (Fig. 2C) . On the other hand, the a-carba-GalCerstimulated production of other cytokines, such as IL-4 or IL-13, IL-2 and IL-17A, was transient, which was similar to the findings with a-GalCer (Fig. 2B and C) . It is interesting that a second wave of cytokine production was observed for IL-10, tumor necrosis factor (TNF)-a and GM-CSF, which peaked at ;36 h after treatment with a-carba-GalCer and a-GalCer. However, the significant augmentation of the second wave was observed only for IL-10 and TNF-a but not GM-CSF after treatment with a-carba-GalCer rather than a-GalCer (Fig. 2B) .
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The IL-12p70 production by DCs and subsequent IFN-c production by NKT cells after a-GalCer stimulation are largely dependent on the interaction between CD40L on NKT cells and CD40 on DCs (24) . Thus, we intraperitoneally administered either anti-IL12 or anti-CD40L 1 day before injection of either a-GalCer or a-carba-GalCer (Fig. 3A and B) . As expected, either blocking of CD40-CD40L interaction or neutralization of IL-12 resulted in suppression of IL-12 and IFN-c production, indicating that the mechanisms of adjuvant effects induced by a-carba-GalCer are based on the IL-12-initiated augmented IFN-c production, similar to those by a-GalCer.
We then tested which cell types are responsible for a-carba-GalCer-mediated IL-12 production. Spleen cells were collected 1 h after a-GalCer or a-carba-GalCer administration, cultured for 5 h in vitro and analyzed for IL-12-producing cells by intracellular cytokine staining. Both a-GalCer and a-carba-GalCer led to IL-12 production from CD11c + DCs (Fig. 3C) . Furthermore, the ratio of IL-12-producing DCs was higher in DCs from a-carba-GalCer-injected mice (1.22%) than those from those given a-GalCer (0.85%) (Fig. 3C) .
We then asked which DC subsets are responsible for IL-12 production. CD11c
+ DCs in Fig. 3C were further divided into CD8a
À conventional DCs (CDCs), CD8a + CDCs and B220 + plasmacytoid DCs (PDCs) on the basis of expression of CD8a and B220. IL-12 was mainly produced from CD8a + CDC rather than CD8a À CDCs or PDCs (Fig. 3D) . We also observed a significant number of IL-12-producing CD11c + CD8a + CDCs by administration of a-carba-GalCer rather than a-GalCer (Fig. 3D) .
To confirm the mechanisms of the production of IL-12 and subsequent IFN-c, we co-cultured freshly isolated splenic NKT cells with a-GalCer-pulsed or a-carba-GalCer-pulsed GM-CSF-induced BMDCs, which phenotypically and functionally resemble to CD8a
+ CDCs. The a-carba-GalCerpulsed DCs produced higher amounts of IL-12p70 compared with those pulsed with a-GalCer and induced augmented IFN-c production by NKT cells (Fig. 3E) . Moreover, IL-12 and IFN-c production stimulated in vitro by a-carba-GalCer was blocked by either anti-CD40L or anti-IL12Rb2 mAbs (Fig. 3E) , indicating that augmented IFN-c production is dependent on CD40-CD40L interaction and augmented IL-12 production.
NKT cell-mediated adjuvant effects on NK and antigen-specific CD8 + T cells after a-carba-GalCer stimulation in mice
We previously demonstrated that the NKT cell production of IFN-c mediates adjuvant effects, which augment the cytotoxic activity of innate NK cells and also increase in the number of IFN-c-producing CD8 + cytotoxic T cells in the acquired immune system (4, 5) . Therefore, we examined the cytotoxicity of mouse liver MNCs or spleen cells from mice treated 4 days previously with a-GalCer or a-carba-GalCer. The liver MNCs of a-carba-GalCer-treated mice exhibited apparently a higher magnitude of cytotoxicity than a-GalCer at any effector:target ratios (Fig. 4A) . Also, we observed significant expansion (>2-fold) of IFN-c-producing OVA-specific CD8 + T cells by co-administration of a-carba-GalCer with OVA-loaded splenocytes, rather than a-GalCer (Fig. 4B ).
Affinity measurement of the a-carba-GalCer-CD1d complex to soluble NKT TCR
We measured the affinity of Va14/Vb8 binding to the CD1d-glycolipid complex according to the previous studies (11, 24, 25) . Purified invariant Va14 and Vb8.2 heterodimeric recombinant proteins were used for surface plasmon resonance analysis against immobilized a-carba-GalCer-CD1d or a-GalCer-CD1d. We observed similar affinity with a-GalCer-CD1d (K d of 84.3 nM, Fig. 5A , upper panel) to those reported previously (12) . On the other hand, the affinity of the invariant Va14/Vb8.2 to a-carba-GalCer-CD1d (K d of 44.9 nM; Fig. 5A , lower) was slightly higher than that for a-GalCer-CD1d. Comparison of the binding kinetics of the invariant Va14/Vb8.2 demonstrated that the increase in the affinity observed in a-carba-GalCer-CD1d was as much the result of increases in the k on as decreases in the k off (Fig. 5B) .
Stability of a-carba-GalCer
Since a-carba-GalCer has an ether linkage (like a-C-GalCer) instead of the glycosyl (acetal) bond of a-GalCer, it is considered to be resistant to a-glycosidase or hydrolytic enzymes. To test this possibility, we carried out an in vitro microsome assay. Cytochrome P450 (CYP) plays an important role in the oxidative metabolism of numerous endogenous and foreign compounds (26) . Because of manifold actions of CYP, we used mouse liver microsomes for treatment of a-carba-GalCer or a-GalCer in vitro to analyze their stability. In this experiment, we first generated the standard curves that were based on the amounts of IFN-c produced after stimulation of spleen cells with untreated glycolipids. According to the standard curve, we calculated a half-life of the glycolipids by measuring IFN-c production at different time points upon stimulation with the residual glycolipids with assumed concentrations after treatment with liver microsomes (Fig. 5C) . The half-life of a-carba-GalCer was ;40 h, which was twice as long as that of a-GalCer (20-25 h), suggesting that a-carba-GalCer is more stable than a-GalCer in terms of hydroxylation. Fig. 1 . Structure of a-GalCer, a-carba-GalCer and a-C-GalCer. The difference between a-GalCer and a-carba-GalCer is the replacement of the 5a#-oxygen atom of the pyranose ring of D-galactose (5a#-O) by a methylene group. The structure of a-C-GalCer with a C-glycosidic (ether) linkage to the ceramide portion is also shown for their comparison. The ceramide moiety (R) of these glycolipids is also illustrated. 
Effect on proliferation of human PBMCs by treatment with a-carba-GalCer
We then asked whether a-carba-GalCer induces responses in human Va24 NKT cells as well as mouse Va14 NKT cells because a-C-GalCer stimulates mouse NKT cells (20) but not human Va24 NKT cells (27) . We prepared human PBMCs from three healthy volunteers and stimulated the cells with a-GalCer or a-carba-GalCer in vitro for 7 days. Contrary to a-C-GalCer, a-carba-GalCer stimulated human Va24 NKT cells to proliferate in in vitro culture better than a-GalCer did (Fig. 6A) . It is known that human Va24 NKT cells can be divided into CD4
À or CD4 + (28). There was no significant 324 Induction of T h 1-biased cytokine production difference in the ratio of CD4 + :CD4
À cells after stimulation with either a-GalCer or a-carba-GalCer, indicating that both glycolipids reacted in a similar manner to both CD4 À and CD4 + human NKT cell subsets according to their expansion even though percentage of NKT cells in PBMCs and ratio of CD4
À cells in NKT cells were different between individuals ( Fig. 6A and B) . We also measured cytokine production from human Va24 NKT cells after stimulation with a-carbaGalCer (Fig. 6C) . The a-carba-GalCer-stimulated human Va24 NKT cells induced all the cytokines tested better than a-GalCer did. Note that significant IL-12 production and IFN-c production were observed in a-carba-GalCer stimulation rather than a-GalCer, which is in consistent with the results in mice (Figs 2-4) .
Discussion
In the present study, we synthesized a new a-GalCer analogue, a-carba-GalCer, by replacing the 5a#-oxygen atom of the pyranose ring of D-galactose (5a#-O) with a methylene group. Despite this minor change on the sugar moiety, a-carba-GalCer, unlike a-GalCer, shows an ability to produce long-lasting T h 1-shifted responses in vivo, with significantly larger amounts of IFN-c, which induces a strong NKT cellmediated adjuvant activity on NK and CD8 + T cells. The enhanced NKT cell-mediated IFN-c production and T h 1-shifted cytokine production induced by a-carba-GalCer are due to augmented IL-12 production by DCs via CD40-CD40L interaction between CD8a + CDCs and NKT cells (Fig. 3B-D) ; in vivo injection of antibodies against CD40L or IL-12 (Fig. 3B ) or in vitro treatment of antibodies against CD40L or IL-12R (Fig. 3E) inhibit IFN-c production.
One possible explanation for this enhanced T h 1-shifted cytokine production is likely to be the stable structure of a-carba-GalCer compared with a-GalCer. It has been reported that a-C-GalCer bearing a C-glycosidic (ether) linkage to the ceramide portion exhibited enhanced T h 1-activity in mice (20) . Since the ether linkage of a-C-GalCer is stable and would not be degraded by glycosidase, a-CGalCer is considered more resistant against decomposition than a-GalCer in vivo. Thus, it is speculated that an a-C-GalCer-CD1d complex could be maintained for a longer time than a-GalCer, leading to a stable triple complex, and generate enhanced T h 1-biased responses. In fact, NKT cell responses to a-carba-GalCer seem quite similar to those to a-C-GalCer, in terms of T h 1-shifted cytokine production and increased CD40L expression on activated NKT cells. Similarly to a-C-GalCer, a-carba-GalCer has a stable ether linkage instead of the glycosyl (acetal) bond of a-GalCer, indicating that a-carba-GalCer is resistant to degradation by hydroxylation. This speculation is supported by the data obtained by the liver microsome assay demonstrating that a-GalCer is more susceptible to degradation than a-carbaGalCer is (Fig. 5C ). Therefore, a-carba-GalCer could stimulate NKT cells for a longer period than a-GalCer and induce enhanced T h 1 cytokine production.
The second possibility is the more stable high affinity interaction of the NKT TCR with a-carba-GalCer-CD1d complexes (see Fig. 5A and B) than a-GalCer-CD1d complexes. According to the crystal structure of human NKT TCRCD1d-a-GalCer reported by Borg et al. (29) , the 5a#-O of a-GalCer does not make a hydrogen bond with any residues in the complex. Additionally, Pro28 at the CDR1 region of the Va14 TCRa chain is placed at a spatially near position to the 5a#-O of a-GalCer. In the case of a-GalCer, it causes repulsion of the non-polar (hydrophobic) amino acid Pro28 and the hydrophilic 5a#-O. On the other hand, in the case of a-carba-GalCer, the 5a#-O is replaced by a hydrophobic methylene group so that the interaction between the Pro28 and the 5a#-methylene group would be enhanced by the hydrophobic interaction. As a result, the binding of a-carbaGalCer-loaded CD1d to the TCR becomes more stable than that of a-GalCer-loaded CD1d because of a slight increase in their affinity (Fig. 5A and B) . Since Pro28 is conserved in mouse Va14 and human Va24 NKT TCRs, human Va24 NKT cells could also stably bind with the a-carba-GalCer-CD1d in exactly the same way as on mouse NKT cells.
In fact, a-carba-GalCer activates human Va24 NKT cells from healthy volunteers to proliferate and produce cytokines in vitro, whereas a-C-GalCer could not stimulate human NKT cells (Fig. 6 ). This may be explained by the possibility that the glycosidic oxygen atom (glycosidic-O) bridging between the sugar moiety and the ceramide portion is important for presentation by human CD1d. According to the crystal structure of the complex between the glycolipid and mouse CD1d, the hydrogen bond length between the oxygen atom of Thr156 and glycosidic-O is 3.44 Å (19) . Besides, in the crystal structure of the complex between the glycolipid and human a-GalCer, the distance between the oxygen atom of Thr154 and the glycosidic-O is 2.83 Å (9) . Therefore, the Thr154 in human CD1d makes a hydrogen bond with glycosidic-O that is shorter and tighter than that with the Thr156 of mouse CD1d. This indicates that the interaction between the human Thr154 and the glycosidic-O is one of the key hydrogen bonds in the complex between a-GalCer and human CD1d for fixing a-GalCer firmly in binding site of human CD1d. Since the glycosidic-O was replaced with CH 2 in a-C-GalCer, a-C-GalCer could not be presented in human CD1d.
In summary, we have generated an NKT cell neoglycolipid ligand, a-carba-GalCer, the carbocyclic analogue of a-GalCer, by replacement of the 5a#-O of the pyranose ring of D-galactose with CH 2 , by which the interaction between Pro28 ) or a-carba-GalCer (100 ng ml À1 ) were measured by the cytometric bead array system at the indicated time points. Data are means 6 SDs from three healthy volunteers and were repeated three times with similar results.
Induction of T h 1-biased cytokine production 327 at the CDR1 of TCRa chain and 5a#-CH 2 on galactose would be enhanced by the newly created hydrophobic interaction. Moreover, a-carba-GalCer possesses a stable ether linkage instead of a glycosyl (acetal) bond of a-GalCer, which would not be degraded by glycosidase, resulting in being more resistant against decomposition and maintained for a longer time than a-GalCer. These structural changes may increase their stable binding and result in potent induction of T h 1-biased cytokine production. Therefore, a-carba-GalCer would be a potential analogue to induce NKT cell-mediated adjuvant effects for protection against tumor malignancy or virus infection.
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